
    
      Primary objective:

      to study the safety and tolerability of HM10660A, including immunogenicity, as compared to
      PEG-interferon alpha-2a

      Secondary objective:

      to study the pharmacokinetics and pharmacodynamics of HM10660A as compared to PEG-interferon
      alpha-2a
    
  